Nivolumab (Opdivo) for the treatment of melanoma

Introduction

Nivolumab (trade name: Opdivo) has been approved in Germany since June 2015 for the treatment of advanced melanoma in adults. Since May 2016, nivolumab has also been approved for adults with advanced melanoma in combination with the drug ipilimumab.

Since August 2018, nivolumab may also be used as supportive (adjuvant) treatment after the surgical removal of melanoma if the cancer had spread to lymph nodes or to other parts of the body (metastasis).

Melanoma is the most dangerous type of skin cancer. It starts growing in the cells that produce the dark pigment in skin. Melanomas are usually surgically removed. But sometimes they may have already spread to lymph nodes, neighboring tissue or other parts of the body. The aim of adjuvant treatment is to kill any remaining tumor cells in the body to prevent a recurrence.

If the tumor has grown too large to be removed or if it has formed distant metastases, it is called advanced melanoma.

The aim of treatment with this drug is to stimulate the immune system to fight the cancer.

Application

Nivolumab for the treatment of advanced melanoma

Depending on whether nivolumab is used alone or in combination with ipilimumab, the drug is given every two, three or four weeks as an intravenous infusion (IV drip) into the bloodstream. One infusion lasts 30 to 60 minutes.

The treatment is terminated if the disease progresses or if very severe side effects arise.

Nivolumab as adjuvant treatment

When used in adjuvant treatment, nivolumab is given every two weeks as an infusion. The recommended dose will depend on the patient's body weight. One infusion lasts about an hour.

The treatment continues for up to a year.

Other treatments

Patients with advanced melanoma have several treatment options. The options depend on whether they have had treatment before and whether they have a mutated protein in the tumor tissue (BRAF V600 mutation). This protein can lead to uncontrolled tumor growth.

  • For patients who have had previous treatment, the therapy options depend on things like which drug had been used before. The treatment is individually adjusted by their doctor.
  • If it is their first treatment and they have a BRAF V600 mutation, vemurafenib is an option.
  • If it is their first treatment and they do not have a BRAF V600 mutation, pembrolizumab or nivolumab alone are options.

After surgical removal of melanoma that had already spread to the lymph nodes or other parts of the body, the standard treatment is watchful waiting: Patients are examined regularly to detect any recurrence early on.

Assessment

Nivolumab for the treatment of advanced melanoma

In 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to find out whether nivolumab alone has any advantages or disadvantages for people with advanced melanoma when compared with dacarbazine – the standard treatment at the time. On the basis of those results, nivolumab became the new standard treatment for people without a BRAF V600 mutation.

In 2017 and 2018, the manufacturer provided study results which compared the combination of nivolumab plus ipilimumab with nivolumab alone for the treatment of advanced melanoma. In this study too, only people without a BRAF V600 mutation participated.

Nivolumab as adjuvant treatment

In 2018, IQWiG looked into whether adjuvant treatment with nivolumab has any advantages or disadvantages compared with the standard treatment for people after surgical removal of melanoma which had spread to lymph nodes or other parts of the body.

But the manufacturer didn’t provide any suitable data with which to do the assessment. So it remains unclear whether adjuvant treatment with nivolumab has any advantages or disadvantages after the surgical removal of advanced melanoma.

More information

This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of nivolumab (Opdivo).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nivolumab – Benefit assessment according to §35a Social Code Book V; Dossier assessment; Commission A15-27. October 13, 2015. (IQWiG reports; Volume 331).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nivolumab – Addendum to Commission A15-27; Commission A15-50. December 11, 2015. (IQWiG reports; Volume 346).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V; Dossier assessment; Commission A16-35. September 12, 2016. (IQWiG reports; Volume 432).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nivolumab (melanoma) – Addendum to Commission A16-35; Commission A16-68. November 21, 2016. (IQWiG reports; Volume 465).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V; Dossier assessment; Commission A17-27. September 13, 2017. (IQWiG reports; Volume 540).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V (expiry of the decision); Dossier assessment; Commission A18-40. September 13, 2018. (IQWiG reports; Volume 665).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V; Dossier assessment; Commission A18-53. November 29, 2018. (IQWiG reports; Volume 684).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on January 3, 2019
Next planned update: 2022

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.